Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 13/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21378468 | 1.00 | ACACB (0.52) | ACACBPOLBRAB9AHDAC6ALDH1A1 | |
| SCHEMBL21378567 | 0.86 | HRH3 (0.51) | ACACBPOLBRAB9AALDH1A1 | |
| SCHEMBL21378570 | 0.86 | HRH3 (0.51) | ACACBPOLBRAB9AALDH1A1 | |
| SCHEMBL20101836 | 0.84 | ACACB (0.46) | ACACBPOLBRAB9AALDH1A1HTT | |
| SCHEMBL18459333 | 0.83 | RAB9A (0.47) | ACACBPOLBRAB9AALDH1A1HTT | |
| SCHEMBL18459334 | 0.83 | RAB9A (0.47) | ACACBPOLBRAB9AALDH1A1HTT | |
| SCHEMBL19179414 | 0.81 | HDAC6 (0.48) | ACACBPOLBRAB9AHDAC6ALDH1A1 | |
| SCHEMBL14846692 | 0.81 | HDAC6 (0.48) | ACACBPOLBRAB9AHDAC6ALDH1A1 | |
| SCHEMBL21388664 | 0.80 | ALDH1A1 (0.50) | ACACBPOLBRAB9AHDAC6ALDH1A1 | |
| SCHEMBL19179478 | 0.77 | CHKA (0.52) | ACACBPOLBRAB9AHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370758-B2 | IDO-TDO dual inhibitor and related methods of use | CMG PHARMACEUTICAL CO., LTD. (KR) | 2022-06-28 | — | — | US | disclosed |
| WO-2019180686-A1 | IDO-TDO DUAL INHIBITOR AND RELATED METHODS OF USE | CMG PHARMACEUTICAL CO., LTD. (KR) | 2019-09-26 | — | — | WO | disclosed |
| US-20190292150-A1 | IDO-TDO DUAL INHIBITOR AND RELATED METHODS OF USE | CMG PHARMACEUTICAL CO., LTD. (KR) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292150-A1 | IDO-TDO DUAL INHIBITOR AND RELATED METHODS OF USE | IDO1, IDO2, TDO2 | ACACB 2173/4885POLB 3553/4885RAB9A 2763/4885 |
| US-11370758-B2 | IDO-TDO dual inhibitor and related methods of use | IDO1, IDO2, TDO2 | ACACB 2173/4885POLB 3553/4885RAB9A 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.